RT Journal Article
T1 Exogenous hormone use and cutaneous melanoma risk in women: The European Prospective Investigation into Cancer and Nutrition.
A1 Cervenka, Iris
A1 Al Rahmoun, Marie
A1 Mahamat-Saleh, Yahya
A1 Fournier, Agnes
A1 Boutron-Ruault, Marie-Christine
A1 Severi, Gianluca
A1 Caini, Saverio
A1 Palli, Domenico
A1 Ghiasvand, Reza
A1 Veierod, Marit B
A1 Botteri, Edoardo
A1 Tjønneland, Anne
A1 Olsen, Anja
A1 Fortner, Renee T
A1 Kaaks, Rudolf
A1 Schulze, Matthias B
A1 Panico, Salvatore
A1 Trichopoulou, Antonia
A1 Dessinioti, Clio
A1 Niforou, Katerina
A1 Sieri, Sabina
A1 Tumino, Rosario
A1 Sacerdote, Carlotta
A1 Bueno-de-Mesquita, Bas
A1 Sandanger, Torkjel M
A1 Colorado-Yohar, Sandra
A1 Sanchez-Perez, Maria-Jose
A1 Gil Majuelo, Leire
A1 Lujan-Barroso, Leila
A1 Ardanaz, Eva
A1 Merino, Susana
A1 Isaksson, Karolin
A1 Butt, Salma
A1 Ljuslinder, Ingrid
A1 Jansson, Malin
A1 Travis, Ruth C
A1 Khaw, Kay-Tee
A1 Weiderpass, Elisabete
A1 Dossus, Laure
A1 Rinaldi, Sabina
A1 Kvaskoff, Marina
K1 cohort studies
K1 cutaneous melanoma
K1 epidemiology
K1 hormonal treatments
K1 menopausal hormone therapy
K1 oral contraceptives
AB Evidence suggests an influence of sex hormones on cutaneous melanoma risk, but epidemiologic findings are conflicting. We examined the associations between use of oral contraceptives (OCs) and menopausal hormone therapy (MHT) and melanoma risk in women participating in the European Prospective Investigation into Cancer and Nutrition (EPIC). EPIC is a prospective cohort study initiated in 1992 in 10 European countries. Information on exogenous hormone use at baseline was derived from country-specific self-administered questionnaires. We used Cox proportional hazards regression models to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). Over 1992-2015, 1,696 melanoma cases were identified among 334,483 women, whereof 770 cases among 134,758 postmenopausal women. There was a positive, borderline-significant association between OC use and melanoma risk (HR = 1.12, 95% CI = 1.00-1.26), with no detected heterogeneity across countries (phomogeneity = 0.42). This risk increased linearly with duration of use (ptrend = 0.01). Among postmenopausal women, ever use of MHT was associated with a nonsignificant increase in melanoma risk overall (HR = 1.14, 95% CI = 0.97-1.43), which was heterogeneous across countries (phomogeneity = 0.05). Our findings do not support a strong and direct association between exogenous hormone use and melanoma risk. In order to better understand these relations, further research should be performed using prospectively collected data including detailed information on types of hormone, and on sun exposure, which may act as an important confounder or effect modifier on these relations.
PB John Wiley & Sons, Inc.
YR 2019
FD 2019-07-25
LK http://hdl.handle.net/10668/14494
UL http://hdl.handle.net/10668/14494
LA en
NO Cervenka I, Al Rahmoun M, Mahamat-Saleh Y, Fournier A, Boutron-Ruault MC, Severi G, Caini S, et al. Exogenous hormone use and cutaneous melanoma risk in women: The European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2020 Jun 15;146(12):3267-3280.
NO The authors thank all participants in the EPIC cohort for their invaluable contribution to the study. We thank the CERCA Program/Generalitat de Catalunya for their institutional support. We also thank the Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, the Netherlands, for their contribution of the Prospect study to the International EPIC Study. I.C. was supported by a research scholarship from the French Ministry of Research. The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark); German Cancer Aid, German Cancer Research Center, Federal Ministry of Education and Research (Germany); the Italian Association for Cancer Research (AIRC) and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports, Netherlands Cancer Registry, LK Research Funds, Dutch Prevention Funds, Dutch ZON, World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS) Pl13/00061 and Pl13/01162, Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, ISCIII Health Research Funds RD12/0036/0018 (Spain); Cancer Research UK, Medical Research Council (UK); the French National Institute of Health and Medical Research (Inserm), the Mutuelle Générale de l'Education Nationale, the Gustave Roussy Institute, and the French League against Cancer (France); and the Hellenic Health Foundation (Greece). R.G. was supported by a grant (project 6823329) from the Norwegian Cancer Society.
DS RISalud
RD Apr 9, 2025